With a shared goal of educating the public about sepsis, the Rory Staunton Foundation and Roche Diagnostics have partnered to elevate the volume of the conversation about this stealthy killer. It is important that the public, government and the clinical community focus resources to fight sepsis. Millions of people die of sepsis when 80% of sepsis deaths are preventable if caught in time and managed correctly. From this spirit of hope and prevention, Fly to Fight Sepsis was born. Read more about the campaign here.
The overriding goal of The Rory Staunton Foundation for Sepsis Prevention is to ensure that no other child or young adult dies of sepsis resulting from the lack of a speedy diagnosis and immediate medical treatment. Our mission is to reduce the number of sepsis-caused deaths through:
Roche Diagnostics is a leader in the development of laboratory tests that help doctors manage patients with infectious diseases, most recently launching Elecsys® BRAHMS PCT Solution, a breakthrough test in 2016 that aids in the management of sepsis.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com or usdiagnostics.roche.com. All trademarks used or mentioned in this release are protected by law.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.